EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 27 / No 10 (Octobre 2011) Med Sci (Paris), 27 10 (2011) 820-822 References
Free Access
Issue
Med Sci (Paris)
Volume 27, Number 10, Octobre 2011
Page(s) 820 - 822
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20112710009
Published online 21 October 2011
  1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003 ; 3 : 459–465. [CrossRef] [PubMed] [Google Scholar]
  2. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007 ; 26 : 3113–3121. [CrossRef] [PubMed] [Google Scholar]
  3. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003 ; 4 : 111–120. [CrossRef] [PubMed] [Google Scholar]
  4. Dubus P. CDK4, cible thérapeutique des adénocarcinomes pulmonaires porteurs d’une mutation de l’oncogène KRAS. Med Sci (Paris) 2010 ; 26 : 1023–1025. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Blasco RB, Francoz S, Santamaria D, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011 ; 19 : 652–663. [CrossRef] [PubMed] [Google Scholar]
  6. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004 ; 22 : 4456–4462. [CrossRef] [PubMed] [Google Scholar]
  7. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010 ; 5 : 1630–1636. [CrossRef] [PubMed] [Google Scholar]
  8. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010 ; 16 : 2450–2457. [CrossRef] [PubMed] [Google Scholar]
  9. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006 ; 66 : 9483–9491. [CrossRef] [PubMed] [Google Scholar]
  10. Ehrenreiter K, Kern F, Velamoor V, et al. Raf-1 addiction in ras-induced skin carcinogenesis. Cancer Cell 2009 ; 16 : 149–160. [CrossRef] [PubMed] [Google Scholar]
  11. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011 ; 19 : 11–15. [CrossRef] [PubMed] [Google Scholar]
  12. Hatzivassiliou G. Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464 : 431–435. [CrossRef] [PubMed] [Google Scholar]
  13. Bollag G, Hirth P,Tsai J,, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 ; 467 : 596–599. [CrossRef] [PubMed] [Google Scholar]
  14. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 ; 363 : 809–819. [CrossRef] [PubMed] [Google Scholar]
  15. Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010 ; 18 : 63–73. [CrossRef] [PubMed] [Google Scholar]
  16. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009 ; 462 : 104–107. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.